查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
多发性骨髓瘤市场 - 全球规模、份额、趋势分析、机会、预测报告，2019-2029
市场调查报告书
商品编码
1364730

多发性骨髓瘤市场 - 全球规模、份额、趋势分析、机会、预测报告，2019-2029

Multiple Myeloma Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Type ; By Treatment ; By Diagnosis ; By Region
出版日期: | 出版商: Blueweave Consulting | 英文 400 Pages | 商品交期: 2-3个工作天内

价格
简介目录

全球多发性骨髓瘤市场规模将以5.39%的复合年复合成长率稳定成长，到2029年将达到294亿美元。

由于全球对多发性骨髓瘤治疗和管理的兴趣日益浓厚以及标靶药物的快速发展，全球多发性骨髓瘤市场正在蓬勃发展。

领先的策略咨询和市场研究公司 BlueWeave Consulting 在最近的研究中估计，2022 年全球多发性骨髓瘤市场规模为 214.6 亿美元。 BlueWeave预测，在2023年至2029年的预测期内，全球多发性骨髓瘤市场规模将以5.39%的年复合成长率成长，到2029年将达到294亿美元。全球多发性骨髓瘤市场的主要成长促进因素包括越来越多地采用 microRNA 疗法。这些创新治疗方法利用 microRNA 的潜力来控制基因表现并监督不同的细胞过程。精确标靶化microRNA治疗方法的进步有望为多发性骨髓瘤提供更个体化和精确的治疗方法。此外，先进医学平台的兴起在推动多发性骨髓瘤市场的扩张方面发挥关键作用。这些多层面的平台涵盖广泛的技术和方法，有助于了解疾病的分子基础、鉴定新的治疗标靶以及开发更有效的治疗方法。透过利用这些复杂平台的力量，研究人员和医疗保健专业人员可以更深入地研究多发性骨髓瘤的复杂性，并推动突破性治疗性介入。然而，高昂的处理成本和严格的法规要求预计将限制预测期内的整体市场成长。

该报告的详细分析提供了有关全球多发性骨髓瘤市场的成长潜力、未来趋势和统计数据的资讯。它还揭示了推动市场总规模预测的要素。该报告承诺提供全球多发性骨髓瘤市场的最新技术趋势和产业见解，以帮助决策者做出明智的策略决策。此外，我们也分析了市场的成长促进因素、挑战和竞争力。

目录

第1章研究框架

第2章执行摘要

第3章全球多发性骨髓瘤市场洞察

  • 产业价值链分析
  • DROC分析
    • 成长促进因素
      • 全球多发性骨髓瘤发生率增加
      • 分子标靶药物的进展
    • 抑制因素
      • 昂贵的治疗费用
      • 严格的法规要求
    • 机会
      • 新兴市场
      • 个人化医疗
    • 任务
      • 竞争
      • 抗药性
  • 科技进步/最新发展
  • 法律规范
  • 波特五力分析

第4章全球多发性骨髓瘤市场概述

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 按类型
      • 冒烟（缓慢进行性）多发性骨髓瘤
      • 活动性（有症状）多发性骨髓瘤
    • 透过治疗
      • 化疗
      • 标靶治疗
      • 免疫调节剂
      • 类固醇
      • 改变骨骼的药物
      • 免疫疗法
      • 骨髓/干细胞移植
      • 放射治疗
      • 外科手术
      • 其他的
    • 透过诊断
      • 血液和尿液检查
      • X射线
      • 磁振造影(MRI)
      • 电脑断层扫描（CT 或 CAT）扫描
      • 正子断层扫描 (PET) 或 PET-CT 扫描
      • 骨髓抽吸和切片检查
      • 抽脂手术
      • 肿瘤生物标记检测
      • 其他的
    • 按地区
      • 北美洲
      • 欧洲
      • 亚太地区 (APAC)
      • 拉丁美洲 (LATAM)
      • 中东和非洲 (MEA)

第5章北美多发性骨髓瘤市场

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 按类型
    • 透过治疗
    • 透过诊断
    • 按国家/地区
      • 美国
      • 加拿大

第6章欧洲多发性骨髓瘤市场

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 按类型
    • 透过治疗
    • 透过诊断
    • 按国家/地区
      • 德国
      • 英国
      • 义大利
      • 法国
      • 西班牙
      • 比利时
      • 俄罗斯
      • 荷兰
      • 其他欧洲国家

第7章亚太多发性骨髓瘤市场

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 按类型
    • 透过治疗
    • 透过诊断
    • 按国家/地区
      • 中国
      • 印度
      • 日本
      • 韩国
      • 澳洲和纽西兰
      • 印尼
      • 马来西亚
      • 新加坡
      • 越南
      • 亚太地区其他国家

第8章拉丁美洲多发性骨髓瘤市场

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 按类型
    • 透过治疗
    • 透过诊断
    • 按国家/地区
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘鲁
      • 拉丁美洲其他地区

第9章中东及非洲多发性骨髓瘤市场

  • 2019-2029年市场规模及预测
    • 按金额
  • 市场占有率及预测
    • 按类型
    • 透过治疗
    • 透过诊断
    • 按国家/地区
      • 沙乌地阿拉伯
      • 阿拉伯聯合大公国
      • 卡达
      • 科威特
      • 南非
      • 奈及利亚
      • 阿尔及利亚
      • MEA 的其余部分

第10章竞争形势

  • 主要企业及其产品列表
  • 2022 年多发性骨髓瘤全球市场占有率分析
  • 透过管理参数进行竞争基准化分析
  • 主要策略发展（合併、收购、合作伙伴关係等）

第11章COVID-19 对全球多发性骨髓瘤市场的影响

12：公司简介（公司简介、财务矩阵、竞争形势、关键人员、主要竞争、联络地址、策略展望、SWOT分析）

  • Sanofi
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Bayer AG
  • Eli Lilly and Company
  • Merck &Co., Inc.
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • AbbVie Inc.
  • Teva Pharmaceutical Industries Ltd
  • ONO Pharmaceutical Co., Ltd
  • Takeda Pharmaceutical Company Ltd
  • Roche Group
  • 其他主要企业

第13章关键战略建议

第14章调查方法

简介目录
Product Code: BWC23812

Global Multiple Myeloma Market Size Grows at Steady CAGR of 5.39% to Reach USD 29.4 Billion by 2029.

Global multiple myeloma market is flourishing because of the growing focus on the treatment and management of increasing incidences of multiple myeloma globally and rapid advancements in targeted drugs.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the global multiple myeloma market size at USD 21.46 billion in 2022. During the forecast period between 2023 and 2029, BlueWeave expects the global multiple myeloma market size to grow at a significant CAGR of 5.39% reaching a value of USD 29.4 billion by 2029. Major growth drivers for the global multiple myeloma market include the increasing adoption of microRNA therapies. These innovative treatment modalities harness the potential of microRNAs to regulate gene expression and oversee diverse cellular processes. The evolution of precisely targeted microRNA therapies holds promise for delivering more individualized and accurate treatments for multiple myeloma. Furthermore, the ascent of advanced biomedicine platforms plays a pivotal role in propelling the expansion of the multiple myeloma market. These multifaceted platforms encompass a wide spectrum of technologies and methodologies that facilitate the understanding of the molecular foundations of the disease, the identification of novel therapeutic targets, and the development of more effective treatment approaches. By harnessing the capabilities of these sophisticated platforms, researchers and healthcare professionals can delve deeper into the intricacies of multiple myeloma, thereby advancing the creation of groundbreaking therapeutic interventions. However, high treatment costs and stringent regulatory requirements are anticipated to restrain the overall market growth during the forecast period.

Global Multiple Myeloma Market - Overview:

The global multiple myeloma market refers to the collective economic and commercial landscape associated with the diagnosis, treatment, and management of multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. The market encompasses various pharmaceutical products, medical devices, diagnostic tools, research initiatives, and healthcare services related to multiple myeloma. It involves the production, distribution, and consumption of drugs, therapies, and technologies aimed at preventing, controlling, or curing multiple myeloma, as well as efforts to enhance patient care, improve outcomes, and advance scientific understanding of the disease. The global multiple myeloma market is influenced by medical advancements, regulatory policies, research and development activities, and the demand for innovative treatment approaches in the global healthcare industry.

Impact of COVID-19 on Global Multiple Myeloma Market

COVID-19 pandemic adversely affected the global multiple myeloma market. The crisis disrupted supply chains, delayed clinical trials, and redirected healthcare resources toward managing the pandemic. Multiple myeloma patients faced challenges in accessing treatments and medical care due to overwhelmed healthcare systems and safety concerns. Telemedicine gained prominence for consultations, but in-person treatments and clinical assessments were often delayed. Additionally, financial strains on healthcare systems affected research funding and hindered the development of new therapies. Despite these setbacks, the pandemic accelerated digital health adoption and emphasized the importance of resilient healthcare systems. The Global Multiple Myeloma Market is adapting to these challenges, but its growth trajectory was undoubtedly impacted by the pandemic.

Global Multiple Myeloma Market - By Treatment

Based on treatment, the global multiple myeloma market is divided into Chemotherapy, Targeted Therapy, Immunomodulatory Drugs, Steroids, Bone-modifying Drugs, Immunotherapy, Bone Marrow/Stem Cell Transplantation, Radiation Therapy, and Surgery segments. The immunomodulatory drugs segment holds the highest share in the global multiple myeloma market by treatment. The prominence of immunomodulators in the market is attributed to various factors, including the increasing prevalence of multiple myeloma and the rising demand for these drugs. Immunomodulators play a crucial role in modifying or delaying the progression of autoimmune, inflammatory, and cancerous conditions, with notable drugs, such as Thalomid, Revlimid, and pomalyst, being used for multiple myeloma treatment. The growing incidence of multiple myeloma is a primary driver, with lenalidomide, an immunomodulatory drug, demonstrating improved outcomes in studies, enhancing progression-free survival, response depth, and overall survival rates. This is expected to boost its adoption among patients and stimulate market growth. Also, increased research and development efforts and a rising number of drug approvals further contribute to market expansion.

Competitive Landscape:

Major players operating in the global multiple myeloma market include: Sanofi, Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Bayer AG, Eli Lilly and Company, Merck & Co., Inc., AstraZeneca, Bristol-Myers Squibb Company, AbbVie Inc., Teva Pharmaceutical Industries Ltd, ONO Pharmaceutical Co., Ltd, Takeda Pharmaceutical Company Ltd, and Roche Group. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Multiple Myeloma Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Multiple Myeloma Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Multiple Myeloma Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. The rising incidence of Multiple Myeloma globally
      • 3.2.1.2. Advancements in targeted drugs
    • 3.2.2. Restraints
      • 3.2.2.1. High treatment costs
      • 3.2.2.2. Stringent regulatory requirements
    • 3.2.3. Opportunities
      • 3.2.3.1. Emerging markets
      • 3.2.3.2. Personalized medicine
    • 3.2.4. Challenges
      • 3.2.4.1. Competition
      • 3.2.4.2. Drug resistance
  • 3.3. Technological Advancements/Recent Developments
  • 3.4. Regulatory Framework
  • 3.5. Porter's Five Forces Analysis
    • 3.5.1. Bargaining Power of Suppliers
    • 3.5.2. Bargaining Power of Buyers
    • 3.5.3. Threat of New Entrants
    • 3.5.4. Threat of Substitutes
    • 3.5.5. Intensity of Rivalry

4. Global Multiple Myeloma Market Overview

  • 4.1. Market Size & Forecast, 2019-2029
    • 4.1.1. By Value (USD Billion)
  • 4.2. Market Share and Forecast
    • 4.2.1. By Type
      • 4.2.1.1. Smoldering (indolent) Multiple Myeloma
      • 4.2.1.2. Active (symptomatic) Multiple Myeloma
    • 4.2.2. By Treatment
      • 4.2.2.1. Chemotherapy
      • 4.2.2.2. Targeted Therapy
      • 4.2.2.3. Immunomodulatory Drugs
      • 4.2.2.4. Steroids
      • 4.2.2.5. Bone-modifying Drugs
      • 4.2.2.6. Immunotherapy
      • 4.2.2.7. Bone Marrow/Stem Cell Transplantation
      • 4.2.2.8. Radiation Therapy
      • 4.2.2.9. Surgery
      • 4.2.2.10. Others
    • 4.2.3. By Diagnosis
      • 4.2.3.1. Blood & Urine Tests
      • 4.2.3.2. X-ray
      • 4.2.3.3. Magnetic Resonance Imaging (MRI)
      • 4.2.3.4. Computed Tomography (CT or CAT) Scan
      • 4.2.3.5. Positron Emission Tomography (PET) or PET-CT Scan
      • 4.2.3.6. Bone Marrow Aspiration and Biopsy
      • 4.2.3.7. Fat Pad Aspirate
      • 4.2.3.8. Biomarker Testing of the Tumor
      • 4.2.3.9. Others
    • 4.2.4. By Region
      • 4.2.4.1. North America
      • 4.2.4.2. Europe
      • 4.2.4.3. Asia Pacific (APAC)
      • 4.2.4.4. Latin America (LATAM)
      • 4.2.4.5. Middle East and Africa (MEA)

5. North America Multiple Myeloma Market

  • 5.1. Market Size & Forecast, 2019-2029
    • 5.1.1. By Value (USD Billion)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type
    • 5.2.2. By Treatment
    • 5.2.3. By Diagnosis
    • 5.2.4. By Country
      • 5.2.4.1. United States
      • 5.2.4.1.1. By Type
      • 5.2.4.1.2. By Treatment
      • 5.2.4.1.3. By Diagnosis
      • 5.2.4.2. Canada
      • 5.2.4.2.1. By Type
      • 5.2.4.2.2. By Treatment
      • 5.2.4.2.3. By Diagnosis

6. Europe Multiple Myeloma Market

  • 6.1. Market Size & Forecast, 2019-2029
    • 6.1.1. By Value (USD Billion)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Treatment
    • 6.2.3. By Diagnosis
    • 6.2.4. By Country
      • 6.2.4.1. Germany
      • 6.2.4.1.1. By Type
      • 6.2.4.1.2. By Treatment
      • 6.2.4.1.3. By Diagnosis
      • 6.2.4.2. United Kingdom
      • 6.2.4.2.1. By Type
      • 6.2.4.2.2. By Treatment
      • 6.2.4.2.3. By Diagnosis
      • 6.2.4.3. Italy
      • 6.2.4.3.1. By Type
      • 6.2.4.3.2. By Treatment
      • 6.2.4.3.3. By Diagnosis
      • 6.2.4.4. France
      • 6.2.4.4.1. By Type
      • 6.2.4.4.2. By Treatment
      • 6.2.4.4.3. By Diagnosis
      • 6.2.4.5. Spain
      • 6.2.4.5.1. By Type
      • 6.2.4.5.2. By Treatment
      • 6.2.4.5.3. By Diagnosis
      • 6.2.4.6. Belgium
      • 6.2.4.6.1. By Type
      • 6.2.4.6.2. By Treatment
      • 6.2.4.6.3. By Diagnosis
      • 6.2.4.7. Russia
      • 6.2.4.7.1. By Type
      • 6.2.4.7.2. By Treatment
      • 6.2.4.7.3. By Diagnosis
      • 6.2.4.8. The Netherlands
      • 6.2.4.8.1. By Type
      • 6.2.4.8.2. By Treatment
      • 6.2.4.8.3. By Diagnosis
      • 6.2.4.9. Rest of Europe
      • 6.2.4.9.1. By Type
      • 6.2.4.9.2. By Treatment
      • 6.2.4.9.3. By Diagnosis

7. Asia-Pacific Multiple Myeloma Market

  • 7.1. Market Size & Forecast, 2019-2029
    • 7.1.1. By Value (USD Billion)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Treatment
    • 7.2.3. By Diagnosis
    • 7.2.4. By Country
      • 7.2.4.1. China
      • 7.2.4.1.1. By Type
      • 7.2.4.1.2. By Treatment
      • 7.2.4.1.3. By Diagnosis
      • 7.2.4.2. India
      • 7.2.4.2.1. By Type
      • 7.2.4.2.2. By Treatment
      • 7.2.4.2.3. By Diagnosis
      • 7.2.4.3. Japan
      • 7.2.4.3.1. By Type
      • 7.2.4.3.2. By Treatment
      • 7.2.4.3.3. By Diagnosis
      • 7.2.4.4. South Korea
      • 7.2.4.4.1. By Type
      • 7.2.4.4.2. By Treatment
      • 7.2.4.4.3. By Diagnosis
      • 7.2.4.5. Australia & New Zealand
      • 7.2.4.5.1. By Type
      • 7.2.4.5.2. By Treatment
      • 7.2.4.5.3. By Diagnosis
      • 7.2.4.6. Indonesia
      • 7.2.4.6.1. By Type
      • 7.2.4.6.2. By Treatment
      • 7.2.4.6.3. By Diagnosis
      • 7.2.4.7. Malaysia
      • 7.2.4.7.1. By Type
      • 7.2.4.7.2. By Treatment
      • 7.2.4.7.3. By Diagnosis
      • 7.2.4.8. Singapore
      • 7.2.4.8.1. By Type
      • 7.2.4.8.2. By Treatment
      • 7.2.4.8.3. By Diagnosis
      • 7.2.4.9. Vietnam
      • 7.2.4.9.1. By Type
      • 7.2.4.9.2. By Treatment
      • 7.2.4.9.3. By Diagnosis
      • 7.2.4.10. Rest of APAC
      • 7.2.4.10.1. By Type
      • 7.2.4.10.2. By Treatment
      • 7.2.4.10.3. By Diagnosis

8. Latin America Multiple Myeloma Market

  • 8.1. Market Size & Forecast, 2019-2029
    • 8.1.1. By Value (USD Billion)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Treatment
    • 8.2.3. By Diagnosis
    • 8.2.4. By Country
      • 8.2.4.1. Brazil
      • 8.2.4.1.1. By Type
      • 8.2.4.1.2. By Treatment
      • 8.2.4.1.3. By Diagnosis
      • 8.2.4.2. Mexico
      • 8.2.4.2.1. By Type
      • 8.2.4.2.2. By Treatment
      • 8.2.4.2.3. By Diagnosis
      • 8.2.4.3. Argentina
      • 8.2.4.3.1. By Type
      • 8.2.4.3.2. By Treatment
      • 8.2.4.3.3. By Diagnosis
      • 8.2.4.4. Peru
      • 8.2.4.4.1. By Type
      • 8.2.4.4.2. By Treatment
      • 8.2.4.4.3. By Diagnosis
      • 8.2.4.5. Rest of LATAM
      • 8.2.4.5.1. By Type
      • 8.2.4.5.2. By Treatment
      • 8.2.4.5.3. By Diagnosis

9. Middle East & Africa Multiple Myeloma Market

  • 9.1. Market Size & Forecast, 2019-2029
    • 9.1.1. By Value (USD Billion)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Treatment
    • 9.2.3. By Diagnosis
    • 9.2.4. By Country
      • 9.2.4.1. Saudi Arabia
      • 9.2.4.1.1. By Type
      • 9.2.4.1.2. By Treatment
      • 9.2.4.1.3. By Diagnosis
      • 9.2.4.2. UAE
      • 9.2.4.2.1. By Type
      • 9.2.4.2.2. By Treatment
      • 9.2.4.2.3. By Diagnosis
      • 9.2.4.3. Qatar
      • 9.2.4.3.1. By Type
      • 9.2.4.3.2. By Treatment
      • 9.2.4.3.3. By Diagnosis
      • 9.2.4.4. Kuwait
      • 9.2.4.4.1. By Type
      • 9.2.4.4.2. By Treatment
      • 9.2.4.4.3. By Diagnosis
      • 9.2.4.5. South Africa
      • 9.2.4.5.1. By Type
      • 9.2.4.5.2. By Treatment
      • 9.2.4.5.3. By Diagnosis
      • 9.2.4.6. Nigeria
      • 9.2.4.6.1. By Type
      • 9.2.4.6.2. By Treatment
      • 9.2.4.6.3. By Diagnosis
      • 9.2.4.7. Algeria
      • 9.2.4.7.1. By Type
      • 9.2.4.7.2. By Treatment
      • 9.2.4.7.3. By Diagnosis
      • 9.2.4.8. Rest of MEA
      • 9.2.4.8.1. By Type
      • 9.2.4.8.2. By Treatment
      • 9.2.4.8.3. By Diagnosis

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Multiple Myeloma Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Multiple Myeloma Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

  • 12.1. Sanofi
  • 12.2. Pfizer Inc.
  • 12.3. GlaxoSmithKline plc
  • 12.4. Novartis AG
  • 12.5. Bayer AG
  • 12.6. Eli Lilly and Company
  • 12.7. Merck & Co., Inc.
  • 12.8. AstraZeneca
  • 12.9. Bristol-Myers Squibb Company
  • 12.10. AbbVie Inc.
  • 12.11. Teva Pharmaceutical Industries Ltd
  • 12.12. ONO Pharmaceutical Co., Ltd
  • 12.13. Takeda Pharmaceutical Company Ltd
  • 12.14. Roche Group
  • 12.15. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents, By Region
  • 14.5. Assumptions & Limitations